We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Biotech ETFs have done quite done well this year as many pharma and biotech companies are working on coronavirus vaccines, therapeutics and testing. Some of these therapeutics, including Gilead’s (GILD - Free Report) antiviral drug remdesivir and Regeneron’s (REGN - Free Report) experimental antibody treatment were given to President Trump.
Genomics stocks and ETFs have been in focus since Dr. Emmanuelle Charpentier and Dr. Jennifer Doudna won the Nobel Prize in Chemistry for their pioneering work in developing the Crispr technology. The revolutionary gene editing technology works like powerful molecular scissors to cut and edit genes in any living creature and has limitless applications.
The ARK Genomic Revolution ETF (ARKG - Free Report) is an actively managed ETF that has surged over 120% this year. Invitae Corporation and CRISPR Therapeutics (CRSP - Free Report) are its top holdings.
To learn more about ARKG, the iShares Genomics Immunology and Healthcare ETF (IDNA - Free Report) and the Global X Genomics & Biotechnology ETF (GNOM - Free Report) , please watch the short video above.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Why You Should Invest in Genomics ETFs
Biotech ETFs have done quite done well this year as many pharma and biotech companies are working on coronavirus vaccines, therapeutics and testing. Some of these therapeutics, including Gilead’s (GILD - Free Report) antiviral drug remdesivir and Regeneron’s (REGN - Free Report) experimental antibody treatment were given to President Trump.
Genomics stocks and ETFs have been in focus since Dr. Emmanuelle Charpentier and Dr. Jennifer Doudna won the Nobel Prize in Chemistry for their pioneering work in developing the Crispr technology. The revolutionary gene editing technology works like powerful molecular scissors to cut and edit genes in any living creature and has limitless applications.
The ARK Genomic Revolution ETF (ARKG - Free Report) is an actively managed ETF that has surged over 120% this year. Invitae Corporation and CRISPR Therapeutics (CRSP - Free Report) are its top holdings.
To learn more about ARKG, the iShares Genomics Immunology and Healthcare ETF (IDNA - Free Report) and the Global X Genomics & Biotechnology ETF (GNOM - Free Report) , please watch the short video above.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>